Home › Research › Treatments
Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease
Fox NC, Black RS, Gilman S, Rossor MN, Griffith SG, Jenkins L, Koller M, AN1792(QS-21)-201 Study.. Neurology, 2005-05-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Background Alzheimer disease (AD) is characterized by progressive cerebral atrophy that may be measured using MRI. Reported are MRI findings of a Phase IIa immunotherapy trial in AD prematurely terminated owing to meningoencephalitis in a subset of patients. Objective To assess cerebral volume changes in patients immunized with AN1792 (beta-amyloid [Abeta] 1 to 42) who were antibody responders (anti-AN1792 IgG titer of > or =1:2,200) compared with placebo patients. Methods This randomized, multicenter, placebo-controlled, double-blind trial of AN1792 225 mug plus QS-21 50 mug included 372 patients with probable AD. Patients received one to three injections of AN1792/QS-21 or saline and were assessed for 12 months. Volumetric MRI was performed pre dose and at month 12 or early termination. Brain, ventricular, and hippocampal volume changes were measured from registered scan pairs. Results Two hundred eighty-eight patients had paired scans (mean interval 10.9 months). Antibody responders (n = 45) had greater brain volume decrease (3.12 +/- 1.98 vs 2.04 +/- 1.74%; p = 0.007), greater ventricular enlargement as a percentage of baseline brain volume (1.10 +/- 0.75 vs 0.48 +/- 0.40%; p Conclusions A dissociation between brain volume loss and cognitive function was observed in AN1792/QS-21 antibody responders. The reasons for this remain unclear but include the possibility that volume changes were due to amyloid removal and associated cerebral fluid shifts.
What this study adds
Evidence grade: High
This is a trial of 45 participants. The authors report that this extra volume loss was not matched by cognitive change and say the reasons "remain unclear", one possibility being "amyloid removal and associated cerebral fluid shifts". Reported effect size: 1.74%; 0.40%.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Fox, N. C., Black, R. S., Gilman, S., Rossor, M. N., Griffith, S. G., Jenkins, L., et al. (2005). Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology. https://doi.org/10.1212/01.wnl.0000159743.08996.99
Vancouver
Fox NC, Black RS, Gilman S, Rossor MN, Griffith SG, Jenkins L, et al. Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology. 2005. doi:10.1212/01.wnl.0000159743.08996.99. PMID: 15883317.
BibTeX
@article{fox2005-15883317,
author = {Fox, N. C. and Black, R. S. and Gilman, S. and Rossor, M. N. and Griffith, S. G. and Jenkins, L. and Koller, M.},
title = {{Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease}},
journal = {Neurology},
year = {2005},
doi = {10.1212/01.wnl.0000159743.08996.99},
pmid = {15883317},
url = {https://doi.org/10.1212/01.wnl.0000159743.08996.99}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 7 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Key findings
- Objective To assess cerebral volume changes in patients immunized with AN1792 (beta-amyloid [Abeta] 1 to 42) who were antibody responders (anti-AN1792 IgG titer of > or =1:2,200) compared with placebo patients.
- Results Two hundred eighty-eight patients had paired scans (mean interval 10.9 months).
Why it matters
In a placebo-controlled trial of the amyloid vaccine AN1792 in 372 people with probable Alzheimer's disease, "prematurely terminated owing to meningoencephalitis in a subset of patients", the 45 people who made antibodies lost more brain volume on MRI over about 11 months than placebo patients (3.12% vs 2.04%; p = 0.007) and had more ventricular enlargement. The authors report that this extra volume loss was not matched by cognitive change and say the reasons "remain unclear", one possibility being "amyloid removal and associated cerebral fluid shifts". Antibody responders are a subgroup of the vaccine arm rather than a randomised group, and the study does not show that the vaccine helped.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Participants45
- Effect size1.74%; 0.40%
- Evidence strengthHigh
How this study scored 76/100
Published in a leading specialty journal, and it is a randomized controlled trial.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Neurology) |
| Journal's citation record | 4 / 4 | Neurology: journal h-index 525 (OpenAlex, 2026-10-29) |
| Study design | 11 / 12 | A randomized controlled trial (from PubMed type “Randomized Controlled Trial”) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2005 — older than 20 years, still counted |
| Sample size | 1 / 4 | 45 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 2 / 2 | Randomized and blinded or placebo-controlled (as stated in the record) |
| Times cited | 6 / 7 | Cited 550 times (OpenAlex, 2026-10-10) |
| Citations per year | 4 / 5 | 23.9 citations a year over 23 year(s) since 2005 |
| Impact for its field and year | 5 / 6 | Cited 31.3× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 4 / 6 | Cited by 44 other studies in this library |
| Still being cited | 2 / 4 | Cited 27 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 1 / 4 | Last-listed author M. Köller: h-index 7 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University of Michigan: institution h-index 2,240 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | PubMed indexes it as a multicentre study |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 15883317) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 76 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription Unpaywall, Europe PMC and OpenAlex found no free copy of the full text (checked 10 Oct 2026), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
44 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Treatments from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.